Menopause Weight Loss Programme
£199 - £397

✓ Appetite Reduction - Lower your appetite for big portions of food using our dietary plan & coaching.

✓ Improve menopause symptoms
such as hot flushes through weight loss.
8

✓ Lasting Weight Loss -
Maintain your weight loss by eliminating emotional eating & unnecessary snacking.

Get Started

Client Transformations

Medicated Weight Loss Program

The chosen medicated treatment is dependent on the outcome of your consultation. We offer Liraglutide, Semaglutide and a variety of other treatments.

True Weight Loss Diet Plan with Video Recipes

You'll be get access to our video recipes which cover all food preferences such as Keto, Vegan or simply standard balanced meals.

True Weight Loss Exercise Programme

You'll also get access to workout programmes that can be done at home using minimal equipment which makes it perfect to suit your busy lifestyles.

24/7 Support

You'll have our team on hand 24/7 to assist you with any of your needs while you're on the programme.

What's included in the programme?

How does it work?

How does it work?

Book Your Consultation

Book your free medical consultation with our advisors by selecting a date and time using our online booking system

Consult Our Medical Team

Our nurse practitioners will determine your suitability and advise your on the best steps to take to hit your weight loss goals

Start Your True Weight Loss Journey

Once you’ve started your programme , you’ll have access to our members area, community and team of medical practitioners to help you every step of the way.
Get Started

Why do you gain weight during menopause?

During the early stages of perimenopause, extremely high levels of estrogen is produced by the ovaries. This is caused by the impaired feedback signals between the ovaries, hypothalamus and pituitary gland. 1

Some studies suggest that high estrogen levels may promote fat gain. This is because high estrogen levels are associated with weight gain and higher body fat. 2 3

In the later stages of perimenopause, estrogen production drops and  even less is produced during menopause.

Low estrogen levels promote fat storage in the belly area as visceral fat, which is linked to insulin resistance and other health problems 4

Researchers also discovered that levels of the “hunger hormone” ghrelin, were higher among perimenopausal women, compared to premenopausal and postmenopausal women.  This can lead to increased appetite which leads to increased calorie intake and weight gain. 5

The low estrogen levels in the late stages of menopause may also impair the function of leptin which is a hormone that controls fullness which further increases appetite and cravings. 6 7

Why is it so hard to lose weight?

There are three main reasons why it's so hard to lose weight during menopause.

1. Your body is in fat storage mode.

When your body stores more visceral fat, it can lead to insulin resistance.

Insulin resistance is when the body has difficulty absorbing glucose from the bloodstream and converting it to energy.

This causes the body  to produce more insulin in an attempt to maintain a normal blood sugar level.

Eventually the body becomes used to overproducing insulin to keep blood sugar level normal.

The high levels of insulin then lead to excessive hunger, increased cravings & in turn, weight gain.

The high insulin levels will also cause the production of "androgens", which are male hormones and one of their effects is weight gain in the abdomen.

2. You experience higher levels of hunger.

Insulin acts as an appetite-stimulating hormone and high levels of insulin may explain why some people experience more hunger.

Intense cravings are reported in women who are insulin resistant and if it isn't managed, these cravings can create bad eating habits leading to higher calorie consumption and weight gain.

3. Your appetite-regulating hormones are impaired.

Appetite-regulating hormones like ghrelin and leptin have been found to be impaired in perimenopausal women. 5

These hormones when at impaired levels stimulate hunger which leads to increased food intake and difficulty managing weight.

Get Started

How Can True Weight Loss Help?

In the True Weight Loss programme, we use clinically backed treatments to help you lose weight during menopause.

And the benefit is even a small amount of weight loss (between 5 - 10 %) could improve symptoms such as hot flushes.8

Our treatment programmes combine increased physical activity and healthier eating with a medicated weight loss service to help you lose weight.

A six month medicated weight loss treatment which included Liraglutide resulted in significant reduction in weight and improvement in quality of life of young women with PCOS and obesity.10

In addition to the medicated treatment, we'll provide you with home-based workout plans and easy to cook healthy video recipes to suit your busy lifestyle.

You'll also have our team of nurse prescribers on hand to answer any of your questions and a digital assistant on hand to help answer any questions online.

Menopausal women have an increased risk of osteoporosis and bone fractures. The risk increases if they try to lose weight and  lose even more bone mass.

A study shows that overweight women can now lose weight with liraglutide without increasing the risk of losing bone mass. 9

4 Week Programme

£197.00 (RRP £349.00)

Expected Weight Loss*: 
Up to 1/2 Stone

What's included?

1x Medicated Weight Loss Treatment

True Weight Loss Diet Plan

True Weight Loss Exercise Plan

Access to Members Area

Access to Facebook Group
Get Started
Individual results may vary*

8 Week Programme

£297.00 (RRP £497.00)

Expected Weight Loss*: 
Up to 1 Stone

What's included?

2x Medicated Weight Loss Treatment

True Weight Loss Diet Plan

True Weight Loss Exercise Plan

Access to Members Area

Access to Facebook Group
Get Started
Individual results may vary*

12 Week Programme

£397.00 (RRP £597.00)

Expected Weight Loss*: 
Up to 1.5 Stone

What's included?

3x Medicated Weight Loss Treatment

True Weight Loss Diet Plan

True Weight Loss Exercise Plan

Access to Members Area

Access to Facebook Group
Get Started
Individual results may vary*

Frequently Asked Questions

Who is best suited for this programme?

The programme is suitable for women aged between 18 and 76, but suitability is fully screened during your consultation.

Who isn't suitable for this programme?

Children under 18, pregnant and breastfeeding women and anyone who has had pancreatitis, thyroid tumours, type 1 diabetics or patients taking insulin medications​.

What medication do you use in your treatment plans?

In addition the diet & exercise programme, our medicated treatment can offer Liraglutide or Semaglutide in oral or injection form.

However this is only available after a consultation with our medical team who will determine your suitability to the treatment.

What are the side effects?

Side effects can vary depending on the treatment  route taken; we will discuss them during your consultation.

A very small minority of our clients (1-2%) have experience at most, low to mild nausea.

However, our medical team is always on hand to assist you and are equipped to handle any side effects that you may experience.

Are there any guarantees?

We cannot provide an absolute guarantee because everyone's weight loss journey is different.
However, our research indicates that 98% of our clients achieved a minimum of 8 lbs weight-loss in 4 weeks.

Do I need to notify my doctor?

You aren’t under any obligation to tell your own GP.

However, we may recommend that you do because  we may request a referral from your GP if your medical is complicated or leaves any doubt to your suitability for the plan.

We will not under any circumstances authorise the treatment for you if we feel that your health would be at risk.


References

1. Prior J. C. (2005). Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine, 26(3), 297–300.

2. O'Sullivan A. J. (2009). Does oestrogen allow women to store fat more efficiently? A biological advantage for fertility and gestation. Obesity reviews : an official journal of the International Association for the Study of Obesity, 10(2), 168–177.

3.Steen B. Pedersen, Kurt Kristensen, Pernille A. Hermann, John A. Katzenellenbogen, Bjørn Richelsen, Estrogen Controls Lipolysis by Up-Regulating α2A-Adrenergic Receptors Directly in Human Adipose Tissue through the Estrogen Receptor α. Implications for the Female Fat Distribution, The Journal of Clinical Endocrinology & Metabolism, Volume 89, Issue 4, 1 April 2004, Pages 1869–1878,

4.Mauvais-Jarvis, F., Clegg, D. J., & Hevener, A. L. (2013). The role of estrogens in control of energy balance and glucose homeostasis. Endocrine reviews, 34(3), 309–338.

5.Sowers, M. R., Wildman, R. P., Mancuso, P., Eyvazzadeh, A. D., Karvonen-Gutierrez, C. A., Rillamas-Sun, E., & Jannausch, M. L. (2008). Change in adipocytokines and ghrelin with menopause. Maturitas, 59(2), 149–157.

6. Boonyaratanakornkit, V., & Pateetin, P. (2015). The role of ovarian sex steroids in metabolic homeostasis, obesity, and postmenopausal breast cancer: molecular mechanisms and therapeutic implications. BioMed research international, 2015, 140196.

7. Lizcano, F., & Guzmán, G. (2014). Estrogen Deficiency and the Origin of Obesity during Menopause. BioMed research international, 2014, 757461. https://doi.org/10.1155/2014/757461

8. Thurston, R. C., Ewing, L. J., Low, C. A., Christie, A. J., & Levine, M. D. (2015). Behavioral weight loss for the management of menopausal hot flashes: a pilot study. Menopause (New York, N.Y.), 22(1), 59–65. https://doi.org/10.1097/GME.0000000000000274

9.Lepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., ... & Torekov, S. S. (2015). GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. The Journal of Clinical Endocrinology & Metabolism, 100(8), 2909-2917.

10. H Kahal, Es Kilpatrick, As Rigby, Am Coady & Sl Atkin (2019) The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls, Gynecological Endocrinology, 35:2, 142-145, DOI: 10.1080/09513590.2018.1505848